Taysha Gene Therapies (NASDAQ:TSHA) Now Covered by Piper Sandler

Piper Sandler initiated coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The firm set an "overweight" rating and a $9.00 price target on the stock. Piper Sandler's target price points to a potential upside of 204.05% from the stock's previous close.

Several other equities analysts also recently weighed in on TSHA. JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Needham & Company LLC raised their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a report on Wednesday, March 20th. Canaccord Genuity Group reiterated a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Chardan Capital lifted their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday, March 21st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $6.88.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA traded up $0.28 during mid-day trading on Tuesday, hitting $2.96. 4,662,399 shares of the company's stock traded hands, compared to its average volume of 2,700,830. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08. The firm's 50 day simple moving average is $2.35 and its 200 day simple moving average is $2.10. Taysha Gene Therapies has a 1 year low of $0.50 and a 1 year high of $3.89. The company has a market cap of $553.58 million, a PE ratio of -4.57 and a beta of 0.29.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds have recently modified their holdings of the stock. Capital Investment Advisors LLC acquired a new stake in shares of Taysha Gene Therapies in the third quarter worth approximately $32,000. AQR Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter worth approximately $38,000. Howard Capital Management Inc. acquired a new position in Taysha Gene Therapies during the fourth quarter valued at approximately $25,000. Maven Securities LTD purchased a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $34,000. Finally, Victory Capital Management Inc. purchased a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $28,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.